Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 5, 2011

FDA Okays BI’s Once-Daily Extended-Release Viramune Tablet for HIV-1 Therapy

  • FDA has approved a once-daily tablet formulation of Boehringer Ingelheim Pharmaceuticals’ Viramune® (nevirapine) drug for treating HIV-1. Extended-release Viramune XR™ is a once-daily, 400 mg formulation of nevirapine approved for use in combination with other antiretroviral agents in adults.

    FDA clearance was based on data from the 48-week Phase III VERxVE trial, which showed that the Viramune XR formulation was as effective, safe, and tolerable as twice-daily immediate-release Viramune (200 mg) in terms of virologic response when used in combination with Truvada® in treatment-naive adult HIV-1 patients. A supporting Phase III study, TRANxITION, also showed that patients who are already being treated using immediate-release Viramune can immediately switch to Viramune XR.

    Patients who have not previously used any formulation of Viramune need to be treated with the immediate-release formulation of the drug twice daily for at least 14 days, to help reduce the incidence of developing a rash, before treatment with Viramune XR can be considered.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »